1. Field of the Invention
The present invention generally relates to fluid handling devices and methods for their use. More particularly, this invention relates to a fluid delivery system and an inline sensing unit capable of delivering controlled amounts of fluids.
2. Description of the Related Art
Infusion therapy generally involves the administration of a medication to a subject using intravenous (IV), subcutaneous and epidural routes. A wide variety of fluid infusion pumps have been developed over the years that are capable of delivering medication at a controlled rate. Such pumps include elastomeric, gravity fed, syringe, electrical and mechanical pumps. Valves and flow sensors have been incorporated into some infusion pump designs to improve dosage accuracy and to control the flow of fluids (e.g., drugs, medications, etc.) through these systems. More recently, micromachined flow sensors, valves and pumps have been developed, some of which have been used in medication and drug delivery applications. Precise fluid control and measurement made possible with the above equipment and devises can also be useful in other medical applications, such as drug compounding and urological and blood analysis.
Certain types of infusion therapies require extremely small amounts of fluids to be delivered in a very precise manner. In these situations, hand-actuated syringes are often not sufficiently accurate. Furthermore, hand-actuated syringes are prone to many types of human errors such as errors in dosage amount, dose rate, and medicine type. Machine-controlled pumps are capable of significantly better accuracy. For example, the accuracy of infusion pumps typically ranges from about +/−15% for volumetric pumps, down to about +/−3% for syringe pumps. Though Coriolis mass flow sensors can provide flow rate measuring accuracies of under +/−1%, their high cost and general requirements for relatively high flow rates have restricted their use in the medical field.
Commonly-assigned U.S. Pat. No. 6,477,901 to Tadigadapa et al. discloses a sensing device having a micromachined resonating tube that operates on the basis of the Coriolis effect to sense mass flow and density of a flowing fluid. The device can sense extremely low volumetric flow rates (e.g., less than 1 ml/hr) of the type required by drug delivery applications. The device uses an electrostatic drive and capacitive sensing, and therefore requires little power for its operation. Commonly-assigned and copending U.S. patent application Ser. No. 10/248,839 to Sparks utilizes the sensing device disclosed in Tadigadapa et al. in a fluid delivery system capable of delivering a precise amount of fluid and monitoring certain properties of the fluid so that the correct fluid is safely delivered to its intended destination. The fluid delivery system of Sparks is also equipped to measure elapsed time and to stop fluid flow in response to output signals of the sensing device. This micromachined sensor is ideal for obtaining the high accuracy, at low power levels and small size that is needed for drug infusion, compounding and medical analysis systems.
While Tadigadapa et al. and Sparks provide significant advancements for infusion systems and treatments, further improvements would be desirable.
The present invention provides a fluid delivery system capable of delivering a precise amount of fluid, such as a fluid required for medical treatment, while also monitoring certain characteristics or properties of the fluid so that the correct fluid is safely delivered in controlled amounts to its intended destination. The system makes use of an inline sensing unit that, in a preferred embodiment, contains a flow sensor of the type disclosed in U.S. Pat. No. 6,477,901 to Tadigadapa et al., wherein a micromachined resonating tube operates on the basis of the Coriolis effect to sense mass flow and/or density of a flowing fluid.
The inline sensing unit of this invention includes a housing comprising an inlet for receiving a fluid from a fluid source, an outlet for discharging the fluid from the housing, and at least one cavity between the inlet and the outlet. A sensing element mounted within the at least one cavity is adapted to have a first response to the density and a second response to the mass flow rate of the fluid flowing between the inlet and the outlet of the housing. Electronic circuitry disposed within the at last one cavity is adapted to produce an electrical output based on at least one of the first and second responses of the sensing element. The inline sensing unit is further equipped with a communication element for providing communication between the electronic circuitry and an electronic device remote from the housing.
A fluid delivery system equipped with the inline sensing unit described above is capable of delivering a precise amount of fluid, in terms of mass flow rate and volumetric flow rate, and can be further used to sense dosage dispensed through the unit. The functionality of the sensing unit can be enhanced to include visual and/or audible signals in response to the density, flow rate, and/or dosage of the fluid. The fluid delivery system can also be equipped to store such data and other information in memory, and/or relay such data and information to a computer Based on the data and information, the flow of the fluid can be stopped if one or more of these parameters are outside preset limits. In this manner, the sensing unit is capable of monitoring blockage. Based on fluid density measurements, the sensing unit is also able to detect gas bubbles or another phase within the fluid, and can determine whether, based on density, the correct fluid is being delivered. This capability can also be employed to prevent medication delivery errors and avoid venous air embolisms.
The inline sensing unit and fluid delivery systems equipped with the sensing unit can be adapted for a variety of applications within and outside the medical industry. If used to intravenously deliver fluids, the sensing unit can be placed inline of a variety of fluid delivery components, including syringes, pipettes, cannula, catheters, Y-ties (Y injection site), septums, machine-controlled pumps, IV primer/drip chambers, etc. In one particular example, the sensing unit is mounted to a manually-operated syringe, with a hypodermic needle mounted to the outlet of the housing. The sensing unit improves the safety and accuracy of manual drug infusion safety performed with syringes by sensing both the mass flow rate and density of the fluid being dispensed, from which the volumetric flow rate and, by the incorporation of a timing device, dosage can be calculated and displayed to the user. Using the preferred sensing element of Tadigadapa et al., the present invention enables manually-operated syringes and pipettes to deliver fluids with nanoliter and microliter control, a capability otherwise impossible with a manually-operated syringe or pipette. As syringes are generally intended to be disposable, the sensing unit of this invention can be manufactured so that the housing comprises a disposable portion in which components that contact the fluid (e.g., the sensing element, inlet, and outlet) are contained, and a separable reusable portion in which components that do not contact the fluid (e.g., the electronic circuitry and communication element) are contained.
Other objects and advantages of this invention will be better appreciated from the following detailed description.
With reference to
According to a preferred aspect of this invention, the sensing unit 12 comprises a housing 18 in which a sensing element 20 and electronic circuitry 22 are enclosed. As indicated in
The sensing element 20 is represented as comprising a tube 30 that serves as a conduit through which the fluid flows as it flows between an inlet and outlet 32 and 34 of the housing 18. The tube 30 has a U-shaped freestanding portion 36 adapted to be vibrated at resonance in a manner that enables certain properties of the fluid to be measured using Coriolis force principles. A preferred Coriolis-type resonating tube flow sensor is taught in U.S. Pat. No. 6,477,901 to Tadigadapa et al., incorporated herein by reference. In Tadigadapa et al., wafer bonding and silicon etching techniques are used to produce a suspended silicon tube on a wafer, the combination of which is simply referred to as the sensing element 20. The freestanding portion 36 of the tube 30 is vibrated at resonance such that, as fluid flows through the tube 30, the freestanding portion 36 twists under the influence of the Coriolis effect. As explained in Tadigadapa et al., the degree to which the freestanding portion 36 twists (deflects) when vibrated can be correlated to the mass flow rate of the fluid flowing through the tube 30 on the basis of the change in the amplitude of a secondary resonant vibration mode. The density of the fluid is proportional to the natural frequency of the fluid-filled vibrating portion 36, such that controlling the vibration of the portion 36 to maintain a frequency at or near its resonant frequency will result in the vibration frequency changing if the density of the fluid flowing through the tube 30 changes. As depicted in
The resonating tube flow sensor of Tadigadapa et al. is preferred for use as the sensing unit 12 of this invention, though it is foreseeable that other types of flow sensors could be employed. However, particularly advantageous aspects of the resonating tube sensor of Tadigadapa et al. include its very small size and its ability to precisely measure extremely small amounts of fluids, in contrast to prior art Coriolis-type flow sensors. Furthermore, the preferred flow sensor can attain flow rate measurement accuracies of under +/−1%, in contrast to other types of infusion pumps whose accuracies can range from about +/−15% for volumetric pumps and +/−3% for syringe pumps. While the high cost and the high flow rate requirements for prior art Coriolis-type flow sensors have restricted their use in the drug delivery arena, the flow sensor of Tadigadapa et al. is able to sense the extremely low flow rates (e.g., less than 1 ml/hr) required by infusion therapy applications. Another advantage is that means for vibrating the tube portion and means for sensing movement of the tube portion of the preferred flow sensor uses an electrostatic drive and capacitive sensing (not shown in
The embodiment of
In the embodiment represented in
As another optional feature, the housing portion 118b is represented as containing an actuator 138 adapted to stop flow of fluid through the housing 118. For example, by forming the inlet 132 to have a pliable membrane or section, the actuator 138 (e.g., in the form of a solenoid) can be operated to pinch or otherwise collapse the pliable section of the inlet 132, thus stopping flow though the housing 118. Alternatively, the actuator 138 could be integrated onto the same micromachined chip as the sensing element 120 to shrink the size and power requirements of the sensing unit 112. Yet another option is to configure the unit 112 to have an actuator capable of pinching an IV tube inserted into the inlet 132 of the housing 118.
Operation of the actuator 138 can be based on a preset condition, such as a specified volume of fluid desired to be dispensed. As discussed above in reference to the embodiment of
An important advantage of the fluid delivery system 110 of
Based on fluid density measurements, the sensing units 12, 112 and 212 are able to detect gas bubbles or another phase within the fluid, and can determine whether, based on density, the correct fluid is being delivered. The safety of an infusion process performed with any of the fluid delivery systems 10, 110 and 210 described above can be promoted with the use of a central computer, such as the computer 26 of
There are a number of drug treatments in which tight flow rate control or dose is critical. Drugs having a narrow therapeutic index (NTI) or range have been defined by the FDA on the basis of the ratio of the median effective dose value of a drug and its median lethal dose or minimum toxic concentration, and whether safe and effective use of the drug requires careful titration and patient monitoring. Such drugs must be administered carefully, as errors in the dose or delivery rate can injure or kill a patient. Additional drugs fall into this category if the patient is an infant or child. Because the sensing units of this invention improve the ability to carefully deliver and monitor the dose of drugs, NTI drugs that are candidates for delivery with this invention include a variety of compounds including, but not restricted to, the following drug or combinations thereof: 5-fluorouracil, acenocumarol, amikacin, aminoglycocides, amniophylline, amphotericin B, anthydisrhythnics, anti-cancer medicines, anticoagulants, anticonvulsants, antifungals, antiretrovirals, carbamazepine, clindamycin, clonidine, coumadin, cyclosporine, depakene, depakote, digitalis glycosides, Digoxin®, Dilantin®, disopyramide, divalproex sodium, dyphilline, eskalith, Gentamicin®, glibenclamide, guanethidine, immunosuppressives, Isoetharine mesylate, isoproterenol, lanoxin, levoxyine, Lidocaine®, lithium, lithium carbonate, Lithobid®, metaporterenol, minoxidil, neural, Norpace®, oxytriphylline, phenobarbital, Phenytoin®, Prazosin®, Primidone®, procainamide, procainbid, pronestyl-sr, quinidine, quinidine gluconate, Quinidix®, quinaglute, Slo-bid®, tacrolimus, Tegretol®, Theo-dur®, theophylline, tobramycin, valproic acid, valproate sodium, vancomycin, Warfarin®, warfarin sodium, and Zidovudine®.
In addition to NTI drugs, other drugs that patients may have an allergic reaction to are excellent candidates for use with the sensing units 12, 112 and 212 of this invention. For this purpose, the flow delivery systems 10, 110 and 210 may serve as means for flowing a fluid through its unit 12, 112 or 212 at a first flow rate and then subsequently at a higher second flow rate, such that the delivery system 10, 110 or 210 can be adapted to gradually administer the drug with very small, gradually increasing doses to begin the desensitization process, permitting the administration of antihistamines if a reaction occurs with the drug. Multiple drugs can be administered in this manner with the sensing units of the invention, including antibiotics and drugs used to treat diseases such as cystic fibrosis, listeria endocarditis and HIV-related PCP.
In view of the above, the sensing units of this invention provide a variety of benefits for a wide array of fluid delivery systems. In addition to the examples given above, the invention provides for an improved syringe pump that conventionally would monitor plunger motion to control drug delivery rates. While low dose syringe pumps can use small syringe barrels to increase their accuracy, the downside is that the total volume that can be pumped accurately with a syringe pump is limited. By inserting a high-accuracy sensing unit of this invention between the syringe and the fluid outlet, a large syringe barrel could be employed while still maintaining high accuracy of small drug volumes because the fluid output is controlled by the sensing unit of this invention instead of the position of the plunger. A stepper motor, often employed in automated syringe pumps, can be used with the invention as an actuator for flow control.
While a timed or preprogrammed dose approach can be taken with the invention, the drug infusion systems described above can also be coupled with other sensors to control the timing and amount of medicines dispensed. For example, a glucose sensor could be used to monitor the glucose level of the blood. When the level goes above or below preset limits, an actuator can be operated to deliver insulin, which is accurately monitored with the sensing unit. Input from the glucose and sensing unit can then used by a computer (e.g., 26 in
As evident from the above, sensing units of this invention can be applied to a number of drug infusion accessories, such as: IV bags, Y-ties, cannula, catheters, PICC (Peripherally Inserted Central Catheter), midline catheters, needle tips, A V (Arterial Venus) fistulas, subcutaneous infusion sets, IV tubing sets, filters, Luer fittings, primers, drip chambers, tubing, septums for needle interfacing, scalp vein infusion sets, hemodialysis sets, etc. Furthermore, the sensing units can be employed in fluid delivery using the IV (intravenous), IA (intra arterial), IM (intramuscular), subcutaneous, oral, nasal, trans dermal, and other routes. For drug infusion it is ideal to put the sensing unit as close to the patient as possible, which may require connection to any of the aforementioned accessories. Doing so would enable the sensing unit to monitor any “pushed” or piggybacked drugs, occlusions or air bubbles that are added to the original fluid be administered.
While the Coriolis-type flow sensor of Tadigadapa et al. has particular features that make it preferred for use with this application, other types of flow sensors could be used. For example, with certain limitations, hot-wire, thin-film, and drag force flow sensors could be employed in the fluid delivery systems of this invention. Furthermore, while medical applications are of particular interest, non-medical applications also exist for the invention, particularly where precise control of liquids is required. Examples include dispensing and mixing of adhesives, inks, and various chemicals. When used with pipettes and pumps, the sensing units of this invention can be used to extract precise amounts of liquid samples commonly required in biological and chemical analysis, research and development.
While the invention has been described in terms of certain embodiments, it is apparent that other forms could be adopted by one skilled in the art. Therefore, the scope of the invention is to be limited only by the following claims.
This application a continuation-in-part patent application of co-pending U.S. patent application Ser. No. 10/248,839 filed Feb. 24, 2003 to Sparks, now U.S. Pat. No. 6,932,114 and claims the benefit of U.S. Provisional Application No. 60/530,961, filed Dec. 10, 2003, and U.S. Provisional Application No. 60/469,134, filed May 12, 2003.
Number | Name | Date | Kind |
---|---|---|---|
4321461 | Walter et al. | Mar 1982 | A |
6477901 | Tadigadapa et al. | Nov 2002 | B1 |
Number | Date | Country | |
---|---|---|---|
20040171983 A1 | Sep 2004 | US |
Number | Date | Country | |
---|---|---|---|
60530961 | Dec 2003 | US | |
60469134 | May 2003 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 10248839 | Feb 2003 | US |
Child | 10708509 | US |